arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Immunome Inc.

IMNM
$24.26 ▼ -1.49 (-5.80%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Immunome Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.7B
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC -11.8%
FCF / Share $-0.56
Trailing P/E
Price / Book 5.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-53.84M
↓ -29.3%
Operating Margin Operating profit as % of sales
-130.0%
↑ +4.0%
FCF / Share Free cash flow per share
$-0.56
↑ +2.5%
Long-Term Debt Long-term obligations
$500.00K
↑ +273.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
22
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 30 quarters